A high-fiber diet may improve response rates and event-free survival outcomes in patients with advanced melanoma receiving standard immunotherapy.

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

The FDA has approved Monjuvi (tafasitamab-cxix) for use in combination with lenalidomide and rituximab to treat adults with relapsed or refractory follicular lymphoma.

Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 ...

An HHS document intended to support the department's change in COVID-19 vaccine policy cites studies that are unpublished or ...

Source: Getty Images "[W]e dissent to Administration policies that undermine the NIH mission, waste public resources, and ...

(HealthDay News) — More than 460 employees who were laid off from their jobs at the US Centers for Disease Control and Prevention (CDC) are being rehired, the Associated Press reported last week.

The program significantly shortens the FDA review time for a sponsor's final drug application submission from approximately 10-12 months to 1-2 months.

A survey of more than 20,000 patients revealed a lack of trust in information about cancer, whether it comes from scientists, doctors, or other sources.

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.